Herbal Antimicrobial Combinations for SIBO
The landmark study on herbal antimicrobials for SIBO is the Chedid et al. (2014) retrospective analysis from Johns Hopkins, which found that herbal therapy achieved a 46% breath test normalization rate compared to 34% for rifaximin (p = 0.24), suggesting at least equivalent efficacy — though the study was not powered to detect superiority.[1]
The Chedid et al. Study
This was a retrospective, open-label study conducted at a tertiary care gastroenterology practice. Of 396 patients who underwent lactulose breath testing (LBT), 251 (63.4%) tested positive for SIBO. Of those, 104 completed treatment and had follow-up LBT — 67 received rifaximin (1200 mg/day for 4 weeks) and 37 received herbal therapy for 4 weeks.[1]
Key results:
- Herbal therapy: 17/37 (46%) achieved a negative follow-up LBT
- Rifaximin: 23/67 (34%) achieved a negative follow-up LBT
- Adjusted odds ratio for negative LBT with herbals vs. rifaximin: 1.85 (CI 0.77–4.41, p = 0.17) — numerically favoring herbals but not statistically significant[1]
A particularly notable finding was the rescue therapy analysis: among 44 rifaximin non-responders, 14 were offered herbal rescue therapy, and 8/14 (57.1%) subsequently achieved a negative LBT, comparable to the 6/10 (60%) who responded to triple antibiotic rescue (p = 0.89).[1]
Adverse events were more common in the rifaximin arm (1 anaphylaxis, 2 hives, 2 diarrhea, 1 C. difficile) compared to only 1 case of diarrhea in the herbal arm, though this difference did not reach statistical significance.[1]
Herbal Products Used in the Chedid Study
The herbal therapy arm used commercially available multi-ingredient botanical formulations. Patients received one of two regimens for 4 weeks:[1][2]
- Dysbiocide and FC Cidal (Biotics Research) — containing a combination of botanical extracts including wormwood, oregano, thyme, and other antimicrobial herbs
- Candibactin-AR and Candibactin-BR (Metagenics) — containing oregano oil/thymol (Candibactin-AR) and berberine-containing herbs such as coptis and Oregon grape (Candibactin-BR)
These are multi-ingredient formulations, making it difficult to attribute efficacy to any single compound.
Individual Herbal Antimicrobial Agents
| Agent | Active Compound(s) | Mechanism of Action | Ref |
|---|---|---|---|
| Oregano oil | Carvacrol, thymol | Disrupts bacterial cell membranes causing lysis and leakage of intracellular contents; inhibits efflux pumps; disrupts preformed biofilms; inhibits bacterial motility; inhibits FtsZ-mediated cell division. Active against both gram-positive and gram-negative bacteria with MICs of 4–16 μg/mL. | [1], [2] |
| Allicin (garlic extract) | Allicin, ajoenes, allyl sulfides | Reactive organosulfur compounds form disulfide bonds with free sulfhydryl groups of bacterial enzymes; compromises bacterial membrane integrity. Exhibits bactericidal, antibiofilm, antitoxin, and anti-quorum sensing activity against a wide range of bacteria including MDR strains. | [3] |
| Berberine-containing herbs (Coptis, Oregon grape) | Berberine | Broad-spectrum antimicrobial; anti-inflammatory via NF-κB inhibition; gut motility modulation; intestinal barrier enhancement. | [4], [5] |
| Wormwood (Artemisia absinthium) | Absinthin, essential oils | Antimicrobial and anti-inflammatory properties; has been studied in Crohn’s disease for steroid-sparing effects. Limited SIBO-specific data. | [6] |
| Neem (Azadirachta indica) | Nimbidin, azadirachtin | Broad antimicrobial activity; anti-inflammatory; used in traditional medicine for GI infections. Minimal SIBO-specific clinical data. | [6] |
Oregano oil is particularly well-studied: its primary constituent carvacrol has demonstrated potent activity against enteric pathogens including E. coli, S. aureus, B. cereus, and even C. difficile biofilms in vitro.[3][4][9] Wild oregano essential oil showed strong inhibitory activity against C. difficile clinical isolates at concentrations of 0.02–1.25 mg/mL, with the best antibiofilm activity among tested essential oils.[9]
Strengths and Limitations
The Chedid study remains the only published clinical study directly comparing herbal antimicrobials to rifaximin for SIBO. Its strengths include a real-world clinical setting and the inclusion of a rescue therapy analysis. However, significant limitations must be acknowledged:[10]
- Retrospective, non-randomized design with inherent selection bias (patients self-selected their treatment)
- Small sample size (n = 104 total) underpowered for definitive conclusions
- Lactulose breath testing was used for diagnosis, which has lower specificity than glucose breath testing or jejunal aspirate
- No blinding or placebo control
- Multi-ingredient formulations make it impossible to determine which specific herbs or compounds drove the effect
- No standardization of herbal product quality or bioactive compound concentrations
- Jadad quality score was low[10]
Current Guideline Perspective
Neither the ACG nor the AGA guidelines include herbal antimicrobials in their formal SIBO treatment recommendations, though the AGA acknowledges that “herbal therapies have been used” and notes the Chedid data as hypothesis-generating.[11][12] A systematic review by Nickles et al. (2021) concluded that there is “preliminary evidence for a role of alternative therapies in the treatment of SIBO” but emphasized that “robust clinical trials are generally lacking” and that “large-scale, randomized, placebo-controlled trials are needed.”[10]
Practical Considerations
Key Points
- Herbal products are dietary supplements and not FDA-regulated for quality, potency, or purity — product variability is a real concern.[2]
- Herbal antimicrobials may be most useful as rescue therapy for rifaximin non-responders (57% response rate in the Chedid data) or in patients who cannot access or tolerate rifaximin.[1]
- The cost advantage is notable: herbal formulations are typically far less expensive than rifaximin, which may not be covered by insurance for SIBO in the US.[11]
- Combining herbal antimicrobials with a low-FODMAP diet may enhance efficacy, as demonstrated in a case report using botanical therapy plus dietary modification.[13]
- There is no established optimal duration, though the Chedid study used 4 weeks of treatment.[1]
Overall, herbal antimicrobial combinations represent a promising but insufficiently validated alternative to conventional antibiotics for SIBO. The Chedid data are encouraging, particularly for rescue therapy, but prospective RCTs with standardized formulations and rigorous endpoints are needed before these can be recommended as first-line therapy.
References
- Herbal Therapy Is Equivalent to Rifaximin for the Treatment of Small Intestinal Bacterial Overgrowth. Chedid V, Dhalla S, Clarke JO, et al. Global Advances in Health and Medicine. 2014;3(3):16-24. <doi:10.7453/gahmj.2014.019>
- Small Intestinal Bacterial Overgrowth: How to Diagnose and Treat (And Then Treat Again). Ginnebaugh B, Chey WD, Saad R. Gastroenterology Clinics of North America. 2020;49(3):571-587. <doi:10.1016/j.gtc.2020.04.010>
- The Antibacterial Properties of Phenolic Isomers, Carvacrol and Thymol. Kachur K, Suntres Z. Critical Reviews in Food Science and Nutrition. 2020;60(18):3042-3053. <doi:10.1080/10408398.2019.1675585>
- Study of the Antimicrobial Activity of Carvacrol and Its Mechanism of Action Against Drug-Resistant Bacteria. Zhi Z, Zhou P, He T, et al. Biochemical and Biophysical Research Communications. 2025;757:151643. <doi:10.1016/j.bbrc.2025.151643>
- Antibacterial Properties of Organosulfur Compounds of Garlic. Bhatwalkar SB, Mondal R, Krishna SBN, et al. Frontiers in Microbiology. 2021;12:613077. <doi:10.3389/fmicb.2021.613077>
- Perspectives on Berberine and the Regulation of Gut Microbiota: As an Anti-Inflammatory Agent. Jael Teresa de Jesús QV, Gálvez-Ruíz JC, Márquez Ibarra AA, Leyva-Peralta MA. Pharmaceuticals (Basel, Switzerland). 2025;18(2):193. <doi:10.3390/ph18020193>
- Berberine Chloride Alleviated Intestinal Inflammation and Improved Postoperative Ileus by Regulating Macrophage Polarization via PI3K/AKT Signaling Pathway. He Y, Liu S, Zheng T, et al. Biochimica Et Biophysica Acta. Molecular Basis of Disease. 2025;1871(7):167920. <doi:10.1016/j.bbadis.2025.167920>
- Chinese Herbal Medicine for the Treatment of Small Intestinal Bacterial Overgrowth (SIBO): A Protocol for Systematic Review and Meta-Analysis. Ren X, Di Z, Zhang Z, et al. Medicine. 2020;99(51):e23737. <doi:10.1097/MD.0000000000023737>
- In vitro Anti-Clostridial Action and Potential of the Spice Herbs Essential Oils to Prevent Biofilm Formation of Hypervirulent Clostridioides Difficile Strains Isolated From Hospitalized Patients With CDI. Aleksić A, Stojanović-Radić Z, Harmanus C, Kuijper EJ, Stojanović P. Anaerobe. 2022;76:102604. <doi:10.1016/j.anaerobe.2022.102604>
- Alternative Treatment Approaches to Small Intestinal Bacterial Overgrowth: A Systematic Review. Nickles MA, Hasan A, Shakhbazova A, et al. Journal of Alternative and Complementary Medicine (New York, N.Y.). 2021;27(2):108-119. <doi:10.1089/acm.2020.0275>
- AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. Quigley EMM, Murray JA, Pimentel M. Gastroenterology. 2020;159(4):1526-1532. <doi:10.1053/j.gastro.2020.06.090>
- ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Pimentel M, Saad RJ, Long MD, Rao SSC. The American Journal of Gastroenterology. 2020;115(2):165-178. <doi:10.14309/ajg.0000000000000501>
- Integrative Treatment of Chronic Abdominal Bloating and Pain Associated With Overgrowth of Small Intestinal Bacteria: A Case Report. Kwiatkowski L, Rice E, Langland J. Alternative Therapies in Health and Medicine. 2017;23(4):56-61.
Next: Berberine for SIBO